top of page


“DT56a has anti-estrogenic properties in the breast tissue…”

“significant reduction in the Kupperman index following 12 weeks of treatment, which was sustained throughout the 12 months of treatment”

“Femarelle treatment in postmenopausal women increases BMD without unwanted estrogenic effect.”

“DT56a.. unique nature compared to the compounds currently used for postmenopausal osteoporosis by being bone-forming and not only an anti-resorptive agent”

“Treatment with DT56a resulted in a significant reduction of hot flushes in postmenopausal women… observed within the first month of treatment.”

“DT56a prevents postmenopausal osteoporosis.”

“Femarelle … inhibits menopausal symptoms without thrombogenicity…”

” DT56a was effective against symptomatic vulvo-vaginal atrophy (vaginal dryness)…”

“DT56a decreased menopausal symptoms significantly and in the same degree as HT.”

bottom of page